| 1 |
29338933 | Physiological based pharmacokinetic modeling to estimate in vivo Ki of ketoconazole on renal P-gp using human drug-drug interaction study result of fesoterodine and ketoconazole. | 2018 Feb |
1 |
| 2 |
30742396 | [A role of fesoterodine in treatment of overactive bladder]. | 2018 Dec |
1 |
| 3 |
23266359 | Investigation of ex vivo stability of fesoterodine in human plasma and its simultaneous determination together with its active metabolite 5-HMT by LC-ESI-MS/MS: Application to a bioequivalence study. | 2013 Jan 15 |
1 |
| 4 |
23497983 | Fesoterodine, its active metabolite, and tolterodine bind selectively to muscarinic receptors in human bladder mucosa and detrusor muscle. | 2013 Apr |
1 |
| 5 |
22853865 | Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteers. | 2012 Oct |
1 |
| 6 |
20371737 | Effects of hepatic dysfunction on the single-dose pharmacokinetics of fesoterodine. | 2011 Mar |
1 |
| 7 |
21352267 | Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. | 2011 Aug |
7 |
| 8 |
21391941 | Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a high-throughput radio receptor bioassay. | 2011 Mar |
1 |
| 9 |
21545485 | Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. | 2011 Aug |
1 |
| 10 |
19915829 | The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. | 2010 Feb |
1 |
| 11 |
19145494 | The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine. | 2009 Mar 7 |
3 |
| 12 |
19246724 | Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine. | 2009 Apr |
1 |
| 13 |
19473600 | Influence of food on the pharmacokinetic profile of fesoterodine. | 2009 Jun |
2 |
| 14 |
19761716 | Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. | 2009 Sep |
1 |
| 15 |
19835561 | The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. | 2009 |
6 |
| 16 |
24198608 | Role of fesoterodine in the treatment of overactive bladder. | 2009 Dec 17 |
2 |
| 17 |
19000553 | Pharmacokinetic profile of fesoterodine. | 2008 Nov |
1 |